SCHEMBL619375

SCHEMBL619375

[CH2]CCCCCC[C](C)C

nearest known ligand 0.31

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6929297 1.00 PAOX (0.31) PAOX
SCHEMBL9361770 1.00 PAOX (0.31) PAOX
SCHEMBL9362507 1.00 PAOX (0.31) PAOX
SCHEMBL9365395 1.00 PAOX (0.31) PAOX
SCHEMBL10424508 1.00 PAOX (0.31) PAOX
SCHEMBL987504 1.00
SCHEMBL1694201 1.00 PAOX (0.31) PAOX
SCHEMBL9365366 1.00 PAOX (0.31) PAOX
SCHEMBL9362505 1.00 PAOX (0.31) PAOX
SCHEMBL632214 0.97

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2690085-B1 NORBORNENE-ESTER-BASED DERIVATIVE, METHOD FOR PREPARING SAME, AND USES THEREOF UNIV SANGMYUNG SEOUL INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) 2016-01-20 EP claimed
US-9205232-B2 Balloon for catheter and balloon catheter TERUMO KABUSHIKI KAISHA (JP) 2015-12-08 US claimed
US-20150152039-A1 NORBORNENE-ESTER-BASED DERIVATIVE, METHOD FOR PREPARING SAME, AND USES THEREOF SANGMYUNG UNIVERSITY SEOUL INDUSTRY-ACADEMY COOPERATION FOUNDATION (KR) 2015-06-04 US claimed
EP-2690085-A2 NORBORNENE-ESTER-BASED DERIVATIVE, METHOD FOR PREPARING SAME, AND USES THEREOF Sangmyung University Seoul Industry-Academy Cooperation Foundation (KR) 2014-01-29 EP claimed
US-20140018568-A1 NORBORNENE-ESTER-BASED DERIVATIVE, METHOD FOR PREPARING SAME, AND USES THEREOF KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2014-01-16 US claimed
US-20130085519-A1 BALLOON FOR CATHETER AND BALLOON CATHETER TERUMO KABUSHIKI KAISHA (JP) 2013-04-04 US claimed
US-5563151-A PLATELET ACTIVATING FACTOR RECEPTOR ANTAGONISTS; ANTIINFLAMMATORY AGENTS, ANALGESICS BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) 1996-10-08 US claimed
EP-0623116-A1 AMINO ACID DERIVATIVES AS PAF-RECEPTOR ANTAGONISTS BRITISH BIO-TECHNOLOGY LIMITED (GB) 1994-11-09 EP claimed
WO-1993014072-A1 AMINO ACID DERIVATIVES AS PAF-RECEPTOR ANTAGONISTS BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-07-22 WO claimed
WO-2024071115-A1 MEDICAL LONG BODY, AND BALLOON CATHETER テルモ株式会社 2024-04-04 WO disclosed
WO-2024071117-A1 BALLOON CATHETER テルモ株式会社 2024-04-04 WO disclosed
US-20230127105-A1 Nonaqueous Electrolytic Solution and Nonaqueous Electrolytic Solution Battery MITSUBISHI CHEMICAL CORPORATION (JP) 2023-04-27 US disclosed
EP-4156366-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION BATTERY Mitsubishi Chemical Corporation (JP) 2023-03-29 EP disclosed
CN-115668570-A Nonaqueous electrolyte solution and nonaqueous electrolyte battery 三菱化学株式会社 2023-01-31 CN disclosed
EP-0405788-A2 Di-tert-butyl(hydroxy)phenylthio substituted hydroxamic acid derivatives SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) 1991-01-02 EP disclosed
US-4892680-A OXIDATION RESISTANCE NIPPON OIL CO., LTD. (JP) 1990-01-09 US disclosed
EP-0285267-A2 Pyridine derivatives for treatment and prevention of liver damage, and their preparation YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-10-05 EP disclosed
EP-0276552-A1 1,4-dihydropyridine derivatives and their production YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 1988-08-03 EP disclosed
EP-0109955-B1 RUBBER/METAL COMPOSITES MONSANTO EUROPE S.A./N.V. (BE) 1988-01-20 EP disclosed
EP-0109955-A2 Rubber/metal composites MONSANTO EUROPE S.A./N.V. (BE) 1984-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152039-A1 NORBORNENE-ESTER-BASED DERIVATIVE, METHOD FOR PREPARING SAME, AND USES THEREOF NOTUM, UGT1A8, CYP19A1 PAOX 295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.